Melinda Brown Biography and Net Worth

Director of Precision BioSciences

Melinda Brown is a member of the Precision BioSciences Board of Directors and Chair of the Board’s Audit Committee. Ms. Brown is a financial expert with proven experience leading accounting, finance and enterprise risk management teams in large, public companies. She most recently served as Senior Vice President and Controller of Tapestry, Inc. from September 2012 until her retirement in March 2019. In this capacity, she led, redefined and enhanced the global control function, as well as participated as a key member in the leadership team supporting Tapestry’s significant growth initiatives, including the acquisition and integration of Kate Spade and Stuart Weitzman brands and their multi-functional SAP implementation. Prior to Tapestry, Ms. Brown spent 30 years with PepsiCo, Inc. with her most recent role as Senior Vice President, Global Financial Shared Services and Productivity where she led North American shared services centers, developed PepsiCo’s global finance outsourcing strategy and coordinated global efforts by the Company to deliver multi-year productivity commitments.

Ms. Brown is Chair Emeritus of The University of Connecticut Foundation Board of Directors where she previously served as their Audit Committee Chair and member of their Executive and Finance Committees. Ms. Brown began her career at Coopers Lybrand followed by the Financial Accounting Standards Board. She received a Bachelor of Science in Accounting and a Master of Business Administration from the University of Connecticut. She is a Certified Public Accountant and member of the American Institute of CPAs and Connecticut Society of CPAs.

What is Melinda Brown's net worth?: The estimated net worth of Melinda Brown is at least $206.78 thousand as of December 15th, 2025. Ms. Brown owns 23,346 shares of Precision BioSciences stock worth more than $206,776 as of July 15th. This net worth estimate does not reflect any other assets that Ms. Brown may own. Learn More about Melinda Brown's net worth.
How do I contact Melinda Brown?: The corporate mailing address for Ms. Brown and other Precision BioSciences executives is 302 EAST PETTIGREW STREET SUITE A-100, DURHAM NC, 27701. Precision BioSciences can also be reached via phone at (919) 314-5512 and via email at [email protected]. Learn More on Melinda Brown's contact information.
Has Melinda Brown been buying or selling shares of Precision BioSciences?: Melinda Brown has not been actively trading shares of Precision BioSciences during the past quarter. Most recently, on Monday, December 15th, Melinda Brown bought 1,381 shares of Precision BioSciences stock. The stock was acquired at an average cost of $4.97 per share, with a total value of $6,863.57. Following the completion of the transaction, the director now directly owns 23,346 shares of the company's stock, valued at $116,029.62. Learn More on Melinda Brown's trading history.
Who are Precision BioSciences' active insiders?: Precision BioSciences' insider roster includes Melinda Brown (Director), Geno Germano (Director), Derek Jantz (Insider), Matthew Kane (CEO), John Kelly (CFO), and David Thomson (COO). Learn More on Precision BioSciences' active insiders.
Are insiders buying or selling shares of Precision BioSciences?: In the last twelve months, Precision BioSciences insiders bought shares 5 times. They purchased a total of 11,181 shares worth more than $53,978.57. In the last twelve months, insiders at the sold shares 8 times. They sold a total of 98,557 shares worth more than $407,257.82. The most recent insider tranaction occured on February, 18th when CEO Michael Amoroso sold 20,559 shares worth more than $78,946.56. Insiders at Precision BioSciences own 2.7% of the company. Learn More about insider trades at Precision BioSciences.
Information on this page was last updated on 2/18/2026.

Melinda Brown Insider Trading History at Precision BioSciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/15/2025	Buy	1,381	$4.97	$6,863.57	23,346
9/22/2025	Buy	1,400	$4.89	$6,846.00	21,965
6/25/2025	Buy	1,682	$4.14	$6,963.48	20,565
12/26/2024	Buy	3,016	$4.55	$13,722.80	7,218

Melinda Brown Buying and Selling Activity at Precision BioSciences

Precision BioSciences Company Overview

Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Today's Range

Now: $8.81

$8.01

$8.90

50 Day Range

MA: $7.36

$6.04

$9.28

2 Week Range

Now: $8.81

$3.53

$9.62

Volume

606,194 shs

Average Volume

335,188 shs

Market Capitalization

$227.30 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.25